Roche: taselisib disappoints; Bryan Garnier reviews target
(CercleFinance.com) - On Tuesday an analyst at Bryan Garnier cut his fair value for the Roche share from 275 Swiss francs to 260 Swiss francs, mainly after the pharmaceutical group halted procedures for approval with the FDA, after disappointing phase III results for its drug taselisib.
Taselisib was tested in combination for the treatment of patients with metastatic breast cancer.
Bryan Garnier also said that it is moderating its estimates on Tecentriq, after a comparison of data between two studies.
In addition, the broker maintains its "Neutral" recommendation on the stock.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Taselisib was tested in combination for the treatment of patients with metastatic breast cancer.
Bryan Garnier also said that it is moderating its estimates on Tecentriq, after a comparison of data between two studies.
In addition, the broker maintains its "Neutral" recommendation on the stock.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.